Browsing by Author "Somchai Preechawat"

Filter results by typing the first few letters
Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Atrial fibrillation following heart transplantation: A systematic review and meta-analysis of observational studies
    (2018-11-01) Ronpichai Chokesuwattanaskul; Tarun Bathini; Charat Thongprayoon; Somchai Preechawat; Oisin A. O'Corragain; Pavida Pachariyanon; Patompong Ungprasert; Wisit Cheungpasitporn; Texas Tech University Health Sciences Center at Lubbock; Temple University; King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University; Faculty of Medicine, Siriraj Hospital, Mahidol University; University of Arizona; Mayo Clinic; University of Mississippi Medical Center
    © 2018 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd Objective: Previous studies have suggested a high incidence of atrial fibrillation (AF) in heart transplant recipients. However, incidence trends of AF in heart transplant recipients remain unclear. The study's aims were (1) to investigate the pooled incidence/incidence trends of AF following heart transplantation and (2) to assess the mortality risk of heart transplant recipients with AF. Methods: A literature search for studies that reported the incidence of AF following heart transplantation was conducted using MEDLINE, EMBASE, and The Cochrane Database from inception through March 2018. Pooled incidence and odds ratios (OR) with 95%CI were calculated using a random-effects model. Results: Eighteen studies (2 cohorts from clinical trials and 16 cohort studies) with 5393 heart transplant recipients were enrolled. The pooled estimated incidence of AF in heart transplant was 10.1% (95%CI: 7.6%-13.2%). Meta-analysis based on the type of anastomotic technique demonstrated a pooled estimated incidence of AF following heart transplantation of 18.7% (95%CI: 10.3%-31.5%) and 11.1% (95%CI: 6.5%-18.4%) by biatrial and bicaval techniques, respectively. There was a significant association between AF following a heart transplant and increased mortality risk with a pooled OR of 2.86 (95%CI: 2.08-3.93). Meta-regression analyses showed no significant correlations between the year of study and incidence of AF (P = 0.47) or mortality risk of AF after heart transplantation (P = 0.99). Conclusions: The overall estimated incidence of AF following heart transplantation is 10.1%. There is a significant association between AF and increased mortality after transplantation. Furthermore, incidence and mortality risk of AF following heart transplant does not seem to decrease over time.
  • No Thumbnail Available
    PublicationMetadata only
    Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: A systematic review and meta-analysis
    (2019-04-01) Ronpichai Chokesuwattanaskul; Charat Thongprayoon; Tarun Bathini; Aldo Torres-Ortiz; Oisin A. O'Corragain; Kanramon Watthanasuntorn; Ploypin Lertjitbanjong; Konika Sharma; Somchai Preechawat; Patompong Ungprasert; Paul T. Kröner; Karn Wijarnpreecha; Wisit Cheungpasitporn; King Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn University; Temple University Hospital; Faculty of Medicine, Siriraj Hospital, Mahidol University; University of Arizona; Mayo Clinic; University of Mississippi Medical Center; Mayo Clinic in Jacksonville, Florida; Bassett Medical Center
    © 2018 Editrice Gastroenterologica Italiana S.r.l. Objective: The atrial fibrillation-related stroke is clearly prevented by anticoagulation treatment, however, management of anticoagulation for AF in patients with cirrhosis represents a challenge due to bleeding concerns. To address this issue, a systematic review and meta-analysis of the literature was performed. Methods: A literature search for studies reporting the incidence of AF in patients with cirrhosis was conducted using MEDLINE, EMBASE and Cochrane Database, from inception through July 2018. Results: 7 cohort studies including 19,798 patients with AF and cirrhosis were identified. The use of anticoagulation (%) among included studies ranged from 8.3% to 53.9%. Anticoagulation use for AF in patients with cirrhosis was significantly associated with a reduced risk of stroke, with a pooled HR of 0.58 (95%CI: 0.35–0.96). When compared with no anticoagulation, the use of anticoagulation was not significantly associated with a higher risk of bleeding, with a pooled HR of 1.45 (95%CI: 0.96–2.17). Compared to warfarin, the use of direct oral anticoagulants (DOACs) was associated with a lower risk of bleeding among AF patients with cirrhosis. Conclusion: Our study demonstrates that anticoagulation use for AF in patients with cirrhosis is associated with a reduced risk of stroke, without increasing significantly the risk of bleeding, when compared to those without anticoagulation.
  • No Thumbnail Available
    PublicationMetadata only
    Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: A meta-analysis
    (2019-04-01) Ronpichai Chokesuwattanaskul; Charat Thongprayoon; Tarun Bathini; Oisin A. O'Corragain; Konika Sharma; Somchai Preechawat; Karn Wijarnpreecha; Paul T. Kröner; Patompong Ungprasert; Wisit Cheungpasitporn; Chulalongkorn University; Temple University Hospital; Faculty of Medicine, Siriraj Hospital, Mahidol University; University of Arizona; Mayo Clinic; University of Mississippi Medical Center; Mayo Clinic in Jacksonville, Florida; Bassett Medical Center
    Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. Objective The epidemiology of atrial fibrillation (AF) in patients with cirrhosis and its clinical significance remain unclear. This study aimed (i) to investigate the pooled prevalence and/or incidence of AF in patients with cirrhosis and (ii) to assess the mortality risk of AF in patients with cirrhosis. Patients and methods A literature search for studies that reported incidence of AF in patients with cirrhosis was carried out using Medline, Embase, and Cochrane Database from inception through July 2018. Pooled incidence with 95% confidence interval (CI) was calculated using a random-effect model. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018102664). Results Seven cohort studies including 385 866 patients with cirrhosis were identified. The pooled estimated prevalence of AF in patients with cirrhosis was 5.0% (95% CI: 2.8-8.6%). When studies that solely assessed patients undergoing transplant evaluation or on transplant waiting list were excluded, the pooled estimated prevalence of AF in patients with cirrhosis was 7.4% (95% CI: 3.5-15.2%). There was a significant association between AF and increased mortality risk in cirrhotic patients with a pooled odds ratio of 1.44 (95% CI: 1.36-1.53). Conclusion The overall estimated prevalence of AF among patients with cirrhosis is 5.0%. Our study demonstrates a statistically significant increased mortality risk in cirrhotic patients with AF.